2022

June 2022
A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient
Read more2021

December 2021
CB-103 has been granted an Orphan Designation for the treatment of Acute Lymphoblastic Leukaemia (ALL)
Read more
November 2021
Cellestia presented its poster at SOHC – Swiss Oncology and Hematology Congress
Read more
May 2021
Nature Reviews Drug Discovery Article “Advances in targeting ‘undruggable’ transcription factors with small molecules”
Read more2020

December 2020
Cellestia launches a new drug discovery program to target Transcription Factors
Read more
October 2020
Article in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Sciences”
Read more
September 2020
Cellestia presented promising clinical data of its lead compound CB-103 at ESMO 2020
Read more
August 2020